• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

迈向肌层浸润性膀胱癌的个体化新辅助治疗。

Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.

机构信息

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA.

出版信息

Eur Urol. 2019 Jul;76(1):4-6. doi: 10.1016/j.eururo.2019.02.027. Epub 2019 Mar 2.

DOI:10.1016/j.eururo.2019.02.027
PMID:30833139
Abstract

It has been demonstrated that immune checkpoint blockade has efficacy similar to chemotherapy in the neoadjuvant setting. Biomarkers such as PD-L1 expression levels can be used to rationally design clinical trials aimed at personalizing systemic therapy for patients with muscle-invasive bladder cancer.

摘要

已经证明,免疫检查点阻断在新辅助治疗环境中的疗效与化疗相似。生物标志物,如 PD-L1 表达水平,可用于合理设计临床试验,旨在为肌层浸润性膀胱癌患者的系统治疗实现个体化。

相似文献

1
Towards Personalized Neoadjuvant Therapy for Muscle-invasive Bladder Cancer.迈向肌层浸润性膀胱癌的个体化新辅助治疗。
Eur Urol. 2019 Jul;76(1):4-6. doi: 10.1016/j.eururo.2019.02.027. Epub 2019 Mar 2.
2
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer.新辅助帕博利珠单抗治疗肌层浸润性膀胱癌的分子亚型和免疫浸润对病理反应和结局的影响。
Eur Urol. 2020 Jun;77(6):701-710. doi: 10.1016/j.eururo.2020.02.028. Epub 2020 Mar 9.
3
Updated Results of PURE-01 with Preliminary Activity of Neoadjuvant Pembrolizumab in Patients with Muscle-invasive Bladder Carcinoma with Variant Histologies.PURE-01的更新结果:新辅助派姆单抗在组织学变异的肌层浸润性膀胱癌患者中的初步活性
Eur Urol. 2020 Apr;77(4):439-446. doi: 10.1016/j.eururo.2019.10.026. Epub 2019 Nov 8.
4
Perioperative systemic therapy for bladder cancer.膀胱癌的围手术期全身治疗。
Curr Opin Urol. 2019 May;29(3):220-226. doi: 10.1097/MOU.0000000000000600.
5
Immunotherapy for Urothelial Carcinoma: Current Evidence and Future Directions.尿路上皮癌的免疫治疗:当前证据与未来方向
Curr Urol Rep. 2018 Nov 7;19(12):109. doi: 10.1007/s11934-018-0851-7.
6
Supplementary granulocyte macrophage colony-stimulating factor to chemotherapy and programmed death-ligand 1 blockade decreases local recurrence after surgery in bladder cancer.化疗联合程序性死亡配体 1 阻断及辅助粒细胞巨噬细胞集落刺激因子治疗降低膀胱癌术后局部复发率。
Cancer Sci. 2019 Oct;110(10):3315-3327. doi: 10.1111/cas.14158. Epub 2019 Aug 19.
7
The promise and challenges of neoadjuvant immunotherapy in the management of non-metastatic muscle-invasive bladder cancer.
BJU Int. 2020 Jun;125(6):753-755. doi: 10.1111/bju.15025. Epub 2020 Feb 27.
8
Recent Clinical Trials Explore Immunotherapies for Urothelial Carcinoma.近期临床试验探索尿路上皮癌的免疫疗法。
Oncology (Williston Park). 2019 Apr 15;33(4):132-6.
9
Emerging role of checkpoint inhibition in localized bladder cancer.检查点抑制在局限性膀胱癌中的新作用。
Urol Oncol. 2016 Dec;34(12):548-555. doi: 10.1016/j.urolonc.2016.09.004. Epub 2016 Oct 21.
10
Complete response to anti-PD-L1 antibody in a metastatic bladder cancer associated with novel MSH4 mutation and microsatellite instability.新型 MSH4 突变和微卫星不稳定相关转移性膀胱癌对抗 PD-L1 抗体的完全应答。
J Immunother Cancer. 2020 Mar;8(1). doi: 10.1136/jitc-2019-000128.

引用本文的文献

1
Multi-Omics Analysis of Novel Signature for Immunotherapy Response and Tumor Microenvironment Regulation Patterns in Urothelial Cancer.尿路上皮癌免疫治疗反应及肿瘤微环境调控模式新特征的多组学分析
Front Cell Dev Biol. 2021 Dec 3;9:764125. doi: 10.3389/fcell.2021.764125. eCollection 2021.
2
Immune checkpoint inhibition in upper tract urothelial carcinoma.免疫检查点抑制在上尿路尿路上皮癌中的应用。
World J Urol. 2021 May;39(5):1357-1367. doi: 10.1007/s00345-020-03502-7. Epub 2020 Oct 31.
3
Macrophage correlates with immunophenotype and predicts anti-PD-L1 response of urothelial cancer.
巨噬细胞与免疫表型相关,并可预测尿路上皮癌对 PD-L1 抗体的反应。
Theranostics. 2020 May 25;10(15):7002-7014. doi: 10.7150/thno.46176. eCollection 2020.